Key result
Obicetrapib reduces LDL-C by ~/dL, with greater efficacy as add-on therapy.
Why the study?
Does obicetrapib alone or as an add-on therapy improve lipid profiles in patients?
Meta-Analysis (n=3,512)
Does obicetrapib alone or as an add-on therapy improve lipid profiles in patients?
Answers are grounded in this paper and cite their sources.
Obicetrapib significantly improves atherogenic lipid profiles, particularly when used as an add-on to ezetimibe, though it showed no significant additional effects when combined with statins.
Obicetrapib is a cholesteryl ester transfer protein inhibitor that demonstrated reductions in atherogenic lipoproteins. We systematically searched PubMed, Scopus, and Clinicaltrials.gov for relevant randomized controlled trials from inception until September 2, 2025 to evaluate the efficacy and safety outcomes of obicetrapib as a standalone and add-on therapy. The mean difference (MD) with 95% confidence intervals (CI) was pooled using a random effects model. A total of 3512 patients were included. Obicetrapib significantly reduced low-density lipoprotein cholesterol [MD, −37.45 (95% CI, −43.76 to −31.15), P < 0.001], non-high-density lipoprotein (HDL) cholesterol [MD, −32.04 (95% CI, −38.49 to −25.60), P < 0.001], apolipoprotein B [MD, −24.71 (95% CI, −30.79 to −18.63), P < 0.001] and apolipoprotein A [MD, −39.10 (95% CI, −45.35 to −32.85), P < 0.001]. It significantly increased total cholesterol [MD, +10.41 (95% CI, 3.68–17.15), P < 0.001], HDL cholesterol [MD, +147.98 (95% CI, 129.23–166.54), P < 0.001], apolipoprotein A1 [MD, 55.54 (95% CI, 43.37–67.71)], and apolipoprotein E [MD, 53.24 (95% CI, 39.04–67.44), P < 0.001]. As an add-on therapy to ezetimibe, obicetrapib yielded greater reduction in low-density lipoprotein [MD, −51.99 (95% CI, −61.61 to −42.37), P < 0.001] and non-HDL [MD, −50.32 (−55.42 to −45.21), P < 0.001]. No significant effects were observed when combined with statins.
No takes yet. Share an insight, caveat, or question.
Jha et al. (2026) reported a meta-analysis. Obicetrapib was evaluated on low-density lipoprotein cholesterol (MD -37.45, 95% CI -43.76 to -31.15, p=< 0.001). Obicetrapib reduced low-density lipoprotein cholesterol, with even greater reductions when used as an add-on therapy to ezetimibe.
Synapse has enriched 10 related papers. Consider them for comparative context: